O
ALNY icon

OrbiMed’s Alnylam Pharmaceuticals ALNY Stock Holding History

OrbiMed’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.4M Sell
119,000
-169,800
-59% -$57.8M 0.78% 39
2025
Q4 		$115M Sell
288,800
-12,800
-4% -$5.66M 2.34% 12
2025
Q3 		$138M Sell
301,600
-40,300
-12% -$16.4M 3.23% 6
2025
Q2 		$111M Sell
341,900
-4,200
-1% -$1.16M 2.78% 11
2025
Q1 		$93.5M Sell
346,100
-69,500
-17% -$17.9M 2.23% 14
2024
Q4 		$97.8M Buy
415,600
+165,300
+66% +$43.5M 2.01% 14
2024
Q3 		$68.8M Hold
250,300
– – 1.25% 25
2024
Q2 		$60.8M Buy
+250,300
New +$39.5M 1.2% 24
2024
Q1 		– Sell
-79,400
Closed -$15.2M – 116
2023
Q4 		$15.2M Buy
+79,400
New +$13.5M 0.3% 69
2022
Q4 		– Sell
-250,500
Closed -$50.1K – 117
2022
Q3 		$50.1K Buy
+250,500
New +$47.8M 0.93% 39
2018
Q3 		– Sell
-1,265,966
Closed -$125M – 152
2018
Q2 		$125M Hold
1,265,966
– – 1.49% 20
2018
Q1 		$151M Buy
1,265,966
+324,366
+34% +$41.8M 1.87% 15
2017
Q4 		$120M Sell
941,600
-143,200
-13% -$18M 1.51% 21
2017
Q3 		$127M Buy
1,084,800
+445,600
+70% +$38M 1.22% 27
2017
Q2 		$51M Buy
639,200
+557,000
+678% +$35.6M 0.53% 56
2017
Q1 		$4.21M Buy
+82,200
New +$3.8M 0.05% 121

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's ALNY Position: Q1 2026 in Review

OrbiMed reduced its Alnylam Pharmaceuticals (ALNY) stake by 59% in Q1 2026, selling an estimated $57.8M and leaving 119,000 shares worth $39.4M. The position accounts for 0.78% of the portfolio, ranked #39.

OrbiMed first reported a position in ALNY in Q1 2017 and has held it in 16 quarters since. The position peaked at $151M in Q1 2018. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • OrbiMed held 119,000 shares of Alnylam Pharmaceuticals worth $39.4M as of Q1 2026.
  • OrbiMed sold 169,800 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $57.8M.
  • Alnylam Pharmaceuticals made up 0.78% of OrbiMed's portfolio in Q1 2026, its #39 holding.
  • OrbiMed first reported a position in Alnylam Pharmaceuticals in Q1 2017 and has held it in 16 quarters since.
  • OrbiMed's Alnylam Pharmaceuticals position peaked at $151M in Q1 2018.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.